Table 3 Logistic regression analysis for adverse events

Male

0.477 (0.136–1.670)

0.247

Age (ref. ≥ 70 years)

0.621

19 ~ 29 years

1.000 (0.045–22.175)

30 ~ 39 years

6.000 (0.183-196.271)

40 ~ 49 years

2.250 (0.111–45.723)

50 ~ 59 years

4.500 (0.190-106.823)

60 ~ 69 years

3.500 (0.145–84.694)

Smoking history

1.527 (0.350–6.672)

0.679

Oral ulcer

0.778 (0.217–2.793)

0.700

Genital ulcer

0.750 (0.121–4.640)

0.757

Ocular lesion

1.200 (0.212–6.801)

0.837

Skin lesion

2.640 (0.504–13.835)

0.251

Arthralgia

5.000 (0.576–43.388)

0.144

5.000 (0.576–43.388)

0.144

Previous treatment history

0.846 (0.081–8.894)

0.889

Previous medical history

1.833 (0.429–7.836)

0.413

Concomitant diseases

2.625 (0.702–9.809)

0.151

Concomitant medications

2.832 (0.358–22.386)

0.324

Disease duration (months)

1.0005 (0.989–1.012)

0.937

Total amount of adalimumab (mg)

1.0001 (0.998–1.002)

0.916

Frequency of adalimumab administration (times)

1.004 (0.939–1.074)

0.900